Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    COVID-19 Affects Cancer Caregivers, but Here Are Ways to Support Them
    COVID-19
    COVID-19 Affects Cancer Caregivers, but Here Are Ways to Support Them
    February 19, 2021
    Celebrate Oncology Nurse Leaders During Black History Month
    ONS Leadership
    Celebrate Oncology Nurse Leaders During Black History Month
    February 03, 2021
    Am I Too Shy to Lead?
    Nurse staffing
    Am I Too Shy to Lead?
    January 29, 2021
    Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers
    nursing professional development
    Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers
    January 22, 2021
    The Case of Concurrent Therapy Concerns
    Treatment side effects
    The Case of Concurrent Therapy Concerns
    December 18, 2020
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Ovarian cancer

    MicroRNA May Be Key Factor in High-Grade Ovarian Cancer Development
    Cancer research

    MicroRNA May Be Key Factor in High-Grade Ovarian Cancer Development

    The miR-181a microRNA may turn off two genes and lead to the development of high-grade serous ovarian cancer, researchers reported in Nature Communications. The finding is significant because not much is known about how ovarian cancer develops and it’s difficult to detect in its earlier stages.

    September 09, 2020
    FDA Approves Olaparib Plus Bevacizumab as Maintenance Treatment for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
    U.S. Food and Drug Administration (FDA)

    FDA Approves Olaparib Plus Bevacizumab as Maintenance Treatment for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

    On May 8, 2020, the U.S. Food and Drug Administration (FDA) expanded the indication of olaparib (Lynparza®) to include its combination with bevacizumab for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line, platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)–positive status defined by either a deleterious or suspected deleterious BRCA mutation or genomic instability.

    May 12, 2020
    FDA Approves Niraparib for First-Line Maintenance of Advanced Ovarian Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Niraparib for First-Line Maintenance of Advanced Ovarian Cancer

    On April 29, 2020, the U.S. Food and Drug Administration (FDA) approved niraparib (Zejula®) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. 

    April 30, 2020
    Oncology Drug Reference Sheet: Niraparib
    Treatments

    Oncology Drug Reference Sheet: Niraparib

    Niraparib was approved in October 2019 for patients with homologous recombination deficiency (HRD)-positive advanced ovarian, fallopian tube, or primary peritoneal cancer. 

    February 25, 2020
    Ovarian Cancer: Prevention, Screening, Treatment, and Survivorship Recommendations
    Ovarian cancer

    Ovarian Cancer: Prevention, Screening, Treatment, and Survivorship Recommendations

    Even though its incidence is less common, ovarian cancer is the fifth leading cause of death from cancer in women, according to the American Cancer Society. It also estimated more than 22,000 new cases of ovarian cancer in 2019, with a five-year survival of 47% for all stages.

    February 06, 2020
    The Case of the Belated BRCA Test
    Genetics & genomics

    The Case of the Belated BRCA Test

    Eighteen months after completing surgical debulking and chemotherapy for stage III high-grade serous ovarian cancer, 56-year-old Lily experienced a rising CA-125 level. At her oncologist’s recommendation, Lily started an aromatase inhibitor, but it did not stop the rising tumor marker. After she began experiencing symptoms of bloating and mild abdominal pain, Lily and her oncologist decided to proceed with second-line chemotherapy. As she left the office, Lily remarked that she did not complete genetic testing when she was originally diagnosed because she does not have any children or a family history of ovarian cancer and she was concerned that her insurance would not cover the testing.

    April 16, 2019
    Recent NSAID Use May Improve Ovarian Cancer Survival
    Research

    Recent NSAID Use May Improve Ovarian Cancer Survival

    Researchers have found that use of nonsteroidal anti-inflammatory drugs (NSAIDs) after diagnosis appears to improve survival for patients with epithelial ovarian cancer. The study results were published in Lancet Oncology.

    November 14, 2018
    BRCA Mutations Point to Hereditary Breast and Ovarian Cancer Syndrome
    Genetics & genomics

    BRCA Mutations Point to Hereditary Breast and Ovarian Cancer Syndrome

    Although all cancers have a genetic basis, a subset result from an inherited (i.e., germline) mutation that puts a person at increased risk for certain cancers. Unfortunately, the signs of hereditary cancer are often overlooked or misunderstood. Here’s what oncology nurses need to know about BRCA mutations, one of the more common mutations you’ll see in practice.

    May 24, 2018
    FDA Approves Rucaparib for Treatment of Recurrent Ovarian Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Rucaparib for Treatment of Recurrent Ovarian Cancer

    On April 6, 2018, the U.S. Food and Drug Administration (FDA) approved rucaparib, a poly ADP-ribose polymerase inhibitor, for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

    April 06, 2018
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Olaparib Tablets for Maintenance Treatment in Ovarian Cancer

    On August 17, 2017, the U.S. Food and Drug Administration granted regular approval to olaparib tablets for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.

    August 17, 2017
    ASCO Annual Meeting

    Olaparib Does Not Decrease Quality-of-Life in Patients With Ovarian Cancer

    Patients with platinum-sensitive relapsed (PSR) serous ovarian cancer (SOC) have poor survival outcomes, with the median progression-free survival (PFS) after chemotherapy less than six months in many patients. Based on results from the SOLO2 study that found that maintenance olaparib after response to chemotherapy resulted in a significant improvement in PFS compared to placebo (median PFS = 19.1 versus 5.5 months) in patients with germline BRCA mutation PSR SOC (hazard ratio [HR] = 0.30; 95% CI = 0.22–0.41; p < 0.0001), researchers assessed the impact of health-related quality-of-life (HRQOL). The researchers presented the study at the ASCO Annual Meeting.

    June 02, 2017
    FDA Update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Niraparib for Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    On March 27, 2017, the U.S. Food and Drug Administration (FDA) approved niraparib, a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

    March 28, 2017
    Ovarian cancer

    FDA Approves Rucaparib for Advanced Ovarian Cancer

    On December 19, 2016, the U.S. Food and Drug Administration granted accelerated approval to rucaparib (RUBRACA™, Clovis Oncology Inc.) for treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies.
    December 19, 2016
    Cancer screening

    FDA Recommends Against Ovarian Cancer Screening Tests

    On September 7, 2016, the U.S. Food and Drug Administration (FDA) issued an alert for women about the risks involved with ovarian cancer screening tests. According to the FDA, no current screening test is sensitive enough to identify ovarian cancer without inaccurate results. As such, the FDA is concerned that patients and physicians might be misled by these results and make unnecessary treatment decisions.
    September 08, 2016
    Oncology drug research

    Maintenance Treatment May Prolong Progression-Free Survival in Ovarian Cancer

    Although response rates to chemotherapy are high, 90% of ovarian cancers will recur within two years. A new drug called niraparib is under investigation as maintenance treatment between cycles of platinum-based chemotherapy, and findings from phase III trials have shown promise.
    August 23, 2016
    Ovarian cancer

    BeBRCAware

    ONS Strategic Sponsor Approximately 15 percent of woman with ovarian cancer have a BRCA mutation and every year, many patients with ovarian cancer are not tested for a BRCA mutation. Family history and age are poor predictors of BRCA status in ovarian cancer patients, which is why it is so important for all women with ovarian cancer to be tested. BeBRCAware is a movement to raise awareness about the importance of genetic testing for a BRCA mutation in ovarian cancer.

    July 07, 2016
    Cancer treatments

    Proteins Targeting Tumor Microenviroment May Block Metastatic Ovarian Cancer Growth

    Although some patients can be treated with surgery and chemotherapy, eventually most metastatic ovarian cancers become resistant to treatment. New options are needed for patients with advanced ovarian cancer.
    May 24, 2016
    Cancer treatments

    New Treatment Approach May Be Effective for Aggressive Ovarian Cancer

    Approximately 80% of ovarian cancers are classified as a high-grade serous subtype. Because of this, long-term survival rates are usually low. Researchers in a new study have found a treatment approach that may offer promise for this form of ovarian cancer.
    April 26, 2016
    Intraperitoneal (IP) chemotherapy for metastatic ovarian cancer
    Ovarian cancer

    Effective Treatment for Ovarian Cancer Is Underused

    A new study reported in the Journal of Clinical Oncology has shown that fewer than half of women with metastatic ovarian cancer are receiving an effective treatment that could improve ovarian cancer outcomes.
    October 13, 2015
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Oncology nurse influence
    View All Topics
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2021 Oncology Nursing Society
     
    Back to Top ▲